DE60127712D1 - Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen - Google Patents

Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen

Info

Publication number
DE60127712D1
DE60127712D1 DE60127712T DE60127712T DE60127712D1 DE 60127712 D1 DE60127712 D1 DE 60127712D1 DE 60127712 T DE60127712 T DE 60127712T DE 60127712 T DE60127712 T DE 60127712T DE 60127712 D1 DE60127712 D1 DE 60127712D1
Authority
DE
Germany
Prior art keywords
treatment
receptor agonists
sexual dysfunctions
selective dopamine
dopamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60127712T
Other languages
English (en)
Other versions
DE60127712T2 (de
Inventor
Jorge D Brioni
Teodozyj Kolasa
Gin C Hsieh
Diane L Donnelly-Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27109879&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60127712(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US09/985,974 external-priority patent/US20020103105A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of DE60127712D1 publication Critical patent/DE60127712D1/de
Application granted granted Critical
Publication of DE60127712T2 publication Critical patent/DE60127712T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60127712T 2000-11-22 2001-11-21 Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen Expired - Lifetime DE60127712T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US718311 1985-04-01
US985974 1992-12-04
US71831100A 2000-11-22 2000-11-22
US09/985,974 US20020103105A1 (en) 2000-11-22 2001-11-07 Use of selective dopamine D4 receptor agonists for treating sexual dysfunction
PCT/US2001/043139 WO2002041894A2 (en) 2000-11-22 2001-11-21 Selective dopamine d4 receptor agonists for treating sexual dysfunction

Publications (2)

Publication Number Publication Date
DE60127712D1 true DE60127712D1 (de) 2007-05-16
DE60127712T2 DE60127712T2 (de) 2007-12-27

Family

ID=27109879

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60127712T Expired - Lifetime DE60127712T2 (de) 2000-11-22 2001-11-21 Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen

Country Status (25)

Country Link
EP (1) EP1345608B1 (de)
JP (1) JP2004534725A (de)
KR (1) KR20030051857A (de)
CN (1) CN1531434A (de)
AR (1) AR035600A1 (de)
AT (1) ATE358483T1 (de)
AU (2) AU2002226895B2 (de)
BG (1) BG107810A (de)
BR (1) BR0110450A (de)
CA (1) CA2429383A1 (de)
CZ (1) CZ20031458A3 (de)
DE (1) DE60127712T2 (de)
ES (1) ES2284727T3 (de)
HK (1) HK1059884A1 (de)
HU (1) HUP0402358A3 (de)
IL (1) IL155094A0 (de)
MX (1) MXPA03004547A (de)
NO (1) NO20032304L (de)
NZ (1) NZ525086A (de)
PE (1) PE20020557A1 (de)
PL (1) PL365890A1 (de)
SK (1) SK7242003A3 (de)
TW (1) TWI293254B (de)
UY (1) UY27031A1 (de)
WO (1) WO2002041894A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
CA2486564A1 (en) * 2002-05-23 2003-12-04 Abbott Laboratories Acetamides and benzamides that are useful in treating sexual dysfunction
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
EP1945214A1 (de) 2005-10-29 2008-07-23 Boehringer Ingelheim International GmbH Benzimidazolon-derivate zur behandlung von prämenstruellen und anderen sexuellen störungen der frau
EP2037927B1 (de) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin zur behandlung von harninkontinenz und assoziierten erkrankungen
BRPI0716439B8 (pt) 2006-08-14 2021-05-25 Boehringer Ingelheim Int sistemas de liberação farmacêutico compreendendo flibanserina, processo para preparação e uso dos mesmos
CN101505736A (zh) 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 控制释放***及其制造方法
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
US9353067B2 (en) * 2011-04-10 2016-05-31 Atir Holding S.A. Heterocyclic compounds and uses thereof in the treatment of sexual disorders
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3004727B2 (ja) * 1994-08-05 2000-01-31 ファイザー・インコーポレーテッド ドパミン作動性活性を有するベンゾイミダゾール誘導体
US5945117A (en) * 1998-01-30 1999-08-31 Pentech Pharmaceuticals, Inc. Treatment of female sexual dysfunction
EP0982030A3 (de) * 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituierte Octahydropyrrolo(1,2-a)pyrazinderivate als 5ht 1a Liganden
US6291471B1 (en) * 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males

Also Published As

Publication number Publication date
ATE358483T1 (de) 2007-04-15
HUP0402358A3 (en) 2009-08-28
BG107810A (bg) 2004-02-27
BR0110450A (pt) 2005-02-09
ES2284727T3 (es) 2007-11-16
UY27031A1 (es) 2002-07-31
NZ525086A (en) 2006-07-28
SK7242003A3 (en) 2004-01-08
AU2689502A (en) 2002-06-03
MXPA03004547A (es) 2004-03-26
AU2002226895B2 (en) 2006-10-12
IL155094A0 (en) 2003-10-31
EP1345608B1 (de) 2007-04-04
JP2004534725A (ja) 2004-11-18
HUP0402358A2 (hu) 2005-03-29
AR035600A1 (es) 2004-06-16
KR20030051857A (ko) 2003-06-25
DE60127712T2 (de) 2007-12-27
PL365890A1 (en) 2005-01-10
NO20032304D0 (no) 2003-05-21
TWI293254B (en) 2008-02-11
CN1531434A (zh) 2004-09-22
CA2429383A1 (en) 2002-05-30
PE20020557A1 (es) 2002-06-25
WO2002041894A2 (en) 2002-05-30
EP1345608A2 (de) 2003-09-24
NO20032304L (no) 2003-07-15
HK1059884A1 (en) 2004-07-23
CZ20031458A3 (cs) 2004-02-18
WO2002041894A3 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
DE60005471D1 (de) EP4 Rezeptor selektive Agonisten zur Behandlung der Osteoporose
ATE374182T1 (de) Selektive agonisten des ep4 rezeptors für die behandlung von osteoporose
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
DE60045386D1 (de) Gerät zur thermischen behandlung von bandscheiben
DE60138129D1 (de) Apparat zur behandlung von zähnen
DE60124259D1 (de) Vorrichtung zur behandlung von migräne
DE69924750D1 (de) Gerät zur thermischen behandlung von gewebe
DE69928542D1 (de) 5ht2-agoniste zur behandlung des glaukoms
IS2494B (is) Notkun á morfólínóli til meðhöndlunar á kynferðislegri vanvirkni
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60238268D1 (de) Vorrichtung zur thermischen behandlung
ATE293447T1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60032905D1 (de) Selektive iglur5 rezeptorantagonisten zur behandlung der migräne
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
DE60031790D1 (de) Rar-gamma selektive retinoid-agonisten zur behandlung von emphysemen
DE60127712D1 (de) Selektive dopamin-d4-rezeptoragonisten zur behandlung von sexuellen dysfunktionen
DE60300341D1 (de) Vorrichtung zur Behandlung von Abgas
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60005566D1 (de) Pyranoindole zur glaukombehandlung
DE50009813D1 (de) Kombinationpräparat zur behandlung von sexueller dysfunktion
DE602004026067D1 (de) Gerät zur Behandlung von Füßen
DE50203468D1 (de) Einrichtung zur abgasnachbehandlung

Legal Events

Date Code Title Description
8363 Opposition against the patent
8365 Fully valid after opposition proceedings